Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Wald

Showing results (171-180 of 178) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 178 results.
Immunity|November 13, 2012
Inactivation of the enzyme GSK3α by the kinase IKKi promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17 cell maintenanceMuhammet F Gulen, Katarzyna Bulek, Hui Xiao, et al.
Oncogene|July 9, 2021
Thioredoxin reductase is a major regulator of metabolism in leukemia cellsSheelarani Karunanithi, Ruifu Liu, Yongchun Hou, et al.
Leukemia|July 10, 2021
Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progressionL C Stetson, Dheepa Balasubramanian, Susan Pereira Ribeiro, et al.
Blood Cancer Journal|November 20, 2022
An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial)Huai-Yu Wang, Sha Gong, Guo-Hui Li, et al.
Frontiers in Immunology|August 28, 2020
Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin LymphomaZachary Jackson, Anne Roe, Ashish Arunkumar Sharma, et al.
Eclinicalmedicine|March 21, 2025
Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trialArmin Ghobadi, Paolo F Caimi, Jane S Reese, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2003
European Code Against Cancer and scientific justification: third version (2003)P Boyle, P Autier, H Bartelink, et al.
European Journal of Epidemiology|September 19, 2007
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases, J Danesh, S Erqou, et al.
Pageof 18

Showing results (171-180 of 178) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 178 results.
Immunity|November 13, 2012
Inactivation of the enzyme GSK3α by the kinase IKKi promotes AKT-mTOR signaling pathway that mediates interleukin-1-induced Th17 cell maintenanceMuhammet F Gulen, Katarzyna Bulek, Hui Xiao, et al.
Oncogene|July 9, 2021
Thioredoxin reductase is a major regulator of metabolism in leukemia cellsSheelarani Karunanithi, Ruifu Liu, Yongchun Hou, et al.
Leukemia|July 10, 2021
Single cell RNA sequencing of AML initiating cells reveals RNA-based evolution during disease progressionL C Stetson, Dheepa Balasubramanian, Susan Pereira Ribeiro, et al.
Blood Cancer Journal|November 20, 2022
An effective and chemotherapy-free strategy of all-trans retinoic acid and arsenic trioxide for acute promyelocytic leukemia in all risk groups (APL15 trial)Huai-Yu Wang, Sha Gong, Guo-Hui Li, et al.
Frontiers in Immunology|August 28, 2020
Automated Manufacture of Autologous CD19 CAR-T Cells for Treatment of Non-hodgkin LymphomaZachary Jackson, Anne Roe, Ashish Arunkumar Sharma, et al.
Eclinicalmedicine|March 21, 2025
Treatment of non-Hodgkin lymphoma with point-of-care manufactured CAR T cells: a dual institution, phase 1 trialArmin Ghobadi, Paolo F Caimi, Jane S Reese, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 11, 2003
European Code Against Cancer and scientific justification: third version (2003)P Boyle, P Autier, H Bartelink, et al.
European Journal of Epidemiology|September 19, 2007
The Emerging Risk Factors Collaboration: analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases, J Danesh, S Erqou, et al.
Pageof 18